USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
PDX PHARMACEUTICALS, LLC
Address:
PDX PHARMACEUTICALS, LLC
24 INDEPENDENCE AVE
LAKE OSWEGO, OR 97035-1401
Phone:
N/A
URL:
N/A
EIN:
127379064
DUNS:
25852616
Number of Employees:
N/A
Woman-Owned?:
Yes
Minority-Owned?:
Yes
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $200,000.00 1
STTR Phase I $299,741.00 1

Award List:

Iron functionalized silica as oral phosphate binder to treat hyperphosphatemia

Award Year / Program / Phase:
2012 / STTR / Phase I
Award Amount:
$299,741.00
Agency:
HHS
Principal Investigator:
Wassana Yantasee – 503-418-9306
Research Institution:
OREGON HEALTH AND SCIENCE UNIVERSITY
RI Contact:
Abstract:
DESCRIPTION (provided by applicant): Hyperphosphatemia is universal to end stage chronic kidney disease patients and a majority of dialysis patients totaling of 400,000 in the US and 2 million worldwide. Current oral phosphate binders to treat hyperphosphatemia still have many drawbacks, including a… More

PDX Pharmaceuticals

Award Year / Program / Phase:
2013 / SBIR / Phase I
Award Amount:
$200,000.00
Agency:
HHS
Principal Investigator:
David Castro – 503-418-9306
Abstract:
Over one million women worldwide are diagnosed with breast cancer each year. Roughly 20% of all breast cancers overexpress the human epidennal growth receptor 2 (HER2-positive subtype). HER2-targeted therapies, including Herceptin and lapatinib, account for 55% of the breast cancer therapy market in… More